CLSD - Clearside Biomedical, Inc.
| Previous Close | 0.7900 |
| Open | 0.7977 |
| Bid | 0.7834 x 1200 |
| Ask | 0.8280 x 4000 |
| Day's Range | 0.7915 - 0.8300 |
| 52 Week Range | 0.5600 - 6.7500 |
| Volume | 320,606 |
| Avg. Volume | 943,374 |
| Market Cap | 30.823M |
| Beta (3Y Monthly) | -0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9620 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.40 |
- Thomson Reuters StreetEvents
Edited Transcript of CLSD earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Clearside Biomedical Inc Earnings Call
- American City Business Journals
This Rockville biotech has added another deal to its growth plan
The deal gives RegenxBio an option for exclusive, worldwide commercial licensing rights to the biopharma’s SCS Microinjector, its delivery method for gene therapies.
- PR Newswire
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
- REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside's proprietary, in-office SCS Microinjector™ platform targeting suprachoroidal space delivery - Recent publication in The Journal of ...
- GlobeNewswire
Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference
ALPHARETTA, Ga., Sept. 03, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.
- Zacks
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
- GlobeNewswire
Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update regarding the Company’s 505(b)(2) New Drug Application (NDA) for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) with the U.S. Food and Drug Administration (FDA).
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the second quarter of 2019 and provided a corporate update. “We continue to make progress in leveraging Clearside’s proprietary suprachoroidal space (SCS) injection platform,” said George Lasezkay, Pharm.D., J.D., Clearside’s Chief Executive Officer. “We recently announced an agreement with Aura Biosciences, which broadens the potential use of our SCS Microinjector™ technology into ocular oncology, where there is a significant unmet medical need.
- GlobeNewswire
Clearside Biomedical to Present at the 2019 Wedbush PacGrow Healthcare Conference
ALPHARETTA, Ga., Aug. 06, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire
Clearside Biomedical to Report Second Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, August 7, 2019
ALPHARETTA, Ga., July 31, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire
Clearside Biomedical Announces Multiple Oral Presentations Delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting
“Clearside had a widespread presence at the ASRS Annual Meeting with multiple presentations and publications on our XIPERE™ data, the use of suprachoroidal injection to deliver gene therapy, and the clinical experience with our SCS Microinjector,” stated Thomas A. Ciulla, M.D., MBA, Chief Medical Officer. “Compared to intravitreal injections, our preclinical experience via SCS injection has demonstrated that over 10 times the amount of drug can be delivered to the choroid and retinal pigment epithelial (RPE), with lower exposure to the anterior segment.
- GlobeNewswire
Clearside Biomedical Announces Multiple Oral Presentations to be Given at the American Society of Retinal Specialists (ASRS) Annual Meeting
ALPHARETTA, Ga., July 18, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire
Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma. Aura is developing a novel class of therapies, viral nanoparticle conjugates, designed to selectively bind and eliminate cancer cells without damaging surrounding normal tissues.
- Simply Wall St.
Is Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Balance Sheet A Threat To Its Future?
Investors are always looking for growth in small-cap stocks like Clearside Biomedical, Inc. (NASDAQ:CLSD), with a...
- GlobeNewswire
Clearside Biomedical to Present at the JMP Securities Life Sciences Conference
ALPHARETTA, Ga., June 11, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Thomson Reuters StreetEvents
Edited Transcript of CLSD earnings conference call or presentation 8-May-19 12:30pm GMT
Q1 2019 Clearside Biomedical Inc Earnings Call
- GlobeNewswire
Clearside Biomedical to Present at the UBS Global Healthcare Conference
ALPHARETTA, Ga., May 15, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision.
- GlobeNewswire
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update. “Clearside has a compelling opportunity to leverage our innovative, non-surgical suprachoroidal space (SCS) delivery platform to make a difference for patients with sight-threatening diseases in the U.S. and around the world,” said George Lasezkay, Pharm.D., J.D., Clearside’s Interim Chief Executive Officer. Dr. Lasezkay continued, “We are validating our platform with the potential approval of our first product candidate, XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis, a condition that currently has no approved therapies.
- GlobeNewswire
Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations were made on Clearside’s Suprachoroidal Space (SCS) injection platform at ophthalmology and gene therapy medical meetings in Vancouver, British Columbia. The presentations highlighted the potential benefits of Clearside’s SCS injection platform when utilized in uveitis patients and with gene therapy.
- GlobeNewswire
Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its first quarter 2019 financial results will be reported on Wednesday, May 8, 2019. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 7816049. An archive of the webcast will be available for three months. Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases.
- GlobeNewswire
Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
ALPHARETTA, Ga., April 18, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire
Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Board of Directors has appointed seasoned biopharmaceutical executive George Lasezkay, Pharm.D., J.D. to the position of Interim Chief Executive Officer, effective immediately. Dr. Lasezkay, a current member of the Clearside Board of Directors, succeeds Daniel H. White, who resigned as President and CEO and as a member of the Board of Directors to pursue other opportunities.
- GlobeNewswire
Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference
ALPHARETTA, Ga., April 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Thomson Reuters StreetEvents
Edited Transcript of CLSD earnings conference call or presentation 12-Mar-19 9:00pm GMT
Q4 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host.
